tenofovir

This page shows the latest tenofovir news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

Its main rival is expected to be Gilead’s new fixed-dose regimen Biktarvy, which combines integrase inhibitor bictegravir with the two ingredients in its fast-growing Descovy (emtricitabine/tenofovir alafenamide)

Latest news

Gilead says switching studies back new HIV therapy Biktarvy

The results of Study 1844 showed that patients who transferred to treatment with Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) from Triumeq (abacavir/dolutegravir/lamivudine) were able to maintain their viral suppression over
Gilead’s triple HIV drug approval prompts GSK lawsuit

GSK’s ViiV Healthcare unit has filed a lawsuit against Gilead claiming that its integrase inhibitor bictegravir - which is one of the active ingredients of Biktarvy along with emtricitabine and tenofovir
ViiV starts trial of HIV-preventing injections for women

can defend against the spread of the virus as well as daily dosing with Gilead’s oral pre-exposure prophylaxis (PrEP) therapy Truvada (emtricitabine and tenofovir disoproxil).
GSK’s ViiV gets US okay for two-drug HIV regimen

that adds integrase inhibitor bictegravir to the two ingredients in its fast-growing Descovy (emtricitabine/tenofovir alafenamide) product.
Positive trial results for Janssen’s Symtuza boosts its HIV credentials

The STR provided ‘effective’and ‘durable’viral suppression. Janssen’s darunavir-based single tablet regimen (STR) Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) showed a positive outcome in the treatment of HIV

More from news
Approximately 10 fully matching, plus 89 partially matching documents found.

Latest Intelligence

Choices, choices: the rapidly evolving HIV treatment landscape

With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where
Pharma deals during July 2012

Merck has licensed CMX 157 an oral nucleoside reverse transcriptase inhibitor for treatment of HIV that is 200-fold more potent in vitro than tenofovir (Gilead's product with sales of

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Medical Writer: Great salary and benefits

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior Programme Executive: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Editorial Director – Medical Education – Oxford: Negotiable

Senior Account Manager / Account Director: Great salary and bebefits

Scientific Director: Great salary and bebefits

Senior Account Manager or AD - Medical Communications: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Account Manager – Med Comms – Kent: Salary TBC

Account Manager – Med Comms – London: Salary TBC

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Medical Writer: Great salary and bebefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Subscribe to our email news alerts

PMHub

Add my company

Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...